Premature ovarian insufficiency (POI)

Key takeaways

• Premature ovarian insufficiency (POI) affects around 3.5% of women globally, significantly more than the "1 in 100" figure still widely quoted, and the 2024 international guidelines explicitly state it is not a rare disease.
• Taking HRT for POI is physiological replacement, restoring hormones to levels that should naturally still be present: the risk framework is fundamentally different from HRT in postmenopausal women, and the findings of older studies do not apply.
• Diagnostic delay is common and worsens outcomes, particularly for bone health: if you have had irregular or absent periods before 40 alongside other symptoms and have not been investigated, it is worth pushing for a referral.

If you are under 40 and your periods have become irregular or stopped, if you have been experiencing hot flushes, poor sleep, brain fog, or low mood, and if you have been told it is probably stress, you should read this carefully.

Premature ovarian insufficiency (POI) is more common than most people know, more frequently missed than it should be, and more treatable than many women are led to believe. The 2024 international evidence-based guidelines on POI, jointly published by the European Society of Human Reproduction and Embryology (ESHRE), the American Society for Reproductive Medicine (ASRM), and the International Menopause Society (IMS), represent the most comprehensive clinical update in this area in a decade. They contain 145 recommendations and correct several widely held misconceptions that are still shaping how women experience diagnosis and treatment.

This article is built on those guidelines and the supporting evidence. It covers what POI is, how it is diagnosed, why it is often delayed, what treatment looks like, and what a diagnosis means for your long-term health and fertility.

What is premature ovarian insufficiency (POI)?

Premature ovarian insufficiency (POI): a condition in which the ovaries stop working before the age of 40, leading to low oestrogen levels and, in most cases, irregular or absent periods.

The term POI has largely replaced the older label "premature ovarian failure." That shift in terminology matters. "Failure" implies a permanent, complete shutdown, when actually ovarian function can be intermittent. The ovaries do not always stop entirely: they become unpredictable and insufficient. Up to 5 to 10% of women with POI may still ovulate sporadically, which has important implications for both fertility and contraception.

POI is distinct from early menopause and from standard menopause. Early menopause refers to menopause occurring between the ages of 40 and 45. Standard menopause, defined as 12 consecutive months without a period, typically occurs around age 51 in the UK. POI is not simply menopause arriving early: it is a different condition with a different cause profile, different diagnostic criteria, and a different long-term health picture that requires specific clinical management.

The 2024 international POI guideline, published simultaneously in Climacteric, Human Reproduction Open, and Fertility and Sterility, defines POI as oligo/amenorrhoea (fewer or absent periods) for at least four months combined with elevated blood follicle-stimulating hormone (FSH) levels on two measurements at least four weeks apart, in women under 40.

How common is POI, and why does it matter?

The figure most commonly cited for POI prevalence is "1 in 100" or 1%. That figure is outdated. A 2023 systematic review and meta-analysis published in Climacteric, examining data from across the globe, found that POI affects approximately 3.5% of women overall. Among women who develop POI from an illness, injury, or a health problem caused by medical treatment (e.g. surgery, chemotherapy, radiotherapy), the prevalence is 11.2%. Among those with autoimmune-related POI, it is 10.5%. The 2024 international guideline explicitly states that POI is not a rare disease and that its true burden has been systematically underestimated.

To put the numbers in context: POI affects around 1 in 10,000 women before the age of 20; 1 in 1,000 before 30; and 1 in 100 before 40. When combined with early menopause (ages 40 to 45), the proportion of women experiencing ovarian insufficiency before 45 rises to 12.2%.

This matters for several reasons. A condition that has been framed as rare tends to receive less clinical attention, less research funding, and less awareness among both patients and GPs. Many women with POI have their symptoms attributed to other causes for months or years before anyone asks the right questions. Correcting the prevalence picture is part of correcting that gap.

Symptoms of POI: what you might notice

The most consistent clinical sign of POI is a change in menstrual pattern: periods becoming irregular, infrequent, or stopping entirely before 40. But menstrual change is not always the most obvious presenting feature, and in some women it is not the symptom that first prompts concern.

Symptoms associated with POI include:

• Irregular or absent periods (the primary diagnostic flag)
• Hot flushes and night sweats
• Poor sleep and fatigue
• Low mood, anxiety, and increased emotional sensitivity
• Brain fog and difficulty concentrating
• Low libido and vaginal dryness
• Joint pain and muscle aches
• Difficulty conceiving

What makes POI particularly difficult to identify is that many of these symptoms are quite non-specific. In a woman in her 20s or early 30s, hot flushes are unexpected and may not immediately be associated with ovarian function. Mood changes and brain fog may be diagnosed as anxiety, depression, or burnout. Irregular periods may be attributed to stress, thyroid dysfunction, or PMOS (previously known as PCOS).

The 2024 international guideline explicitly acknowledges this: symptom misattribution is a KEY driver of diagnostic delay, and delay worsens outcomes. If you have been experiencing several of these symptoms and are under 40, it is important to speak to your GP and request an FSH blood test rather than accepting a watch-and-wait approach.

What causes POI?

In the majority of cases, no definitive cause is identified. The 2024 international guideline estimates that 70 to 80% of POI cases are idiopathic, meaning the underlying cause remains unknown despite investigation. But this next part is important: not knowing why POI has occurred, does not mean it cannot be managed effectively.

Genetic causes

Genetic factors account for approximately 20 to 25% of cases where a cause is identified. Turner syndrome, in which one X chromosome is partially or fully absent, is the most common chromosomal cause. Another mutation known as Fragile X is the most common single-gene cause. Women diagnosed with POI are typically offered genetic testing to screen for these gene mutations.

Autoimmune causes

In around 10% of cases, the immune system produces antibodies that attack its own ovarian tissue. Autoimmune thyroid disease (Hashimoto’s or Grave’s disease) and autoimmune adrenal insufficiency (Addison's disease) are the most frequently associated conditions. Women with POI are usually screened for these, as an undetected autoimmune condition alongside POI has its own management implications.

Iatrogenic causes

POI caused by an illness, injury, or health problem that is caused by medical treatment, a diagnostic procedure, or even a doctor's actions is known as iatrogenic POI. Pelvic surgery (for example removal of the ovaries or womb), ablation treatment for endometriosis, chemotherapy, or radiotherapy can all damage ovarian function, sometimes permanently. For women undergoing these treatments, fertility preservation discussions before treatment are crucial.

Environmental and other factors

Evidence linking environmental toxin exposure to POI is less well established; however, smoking is associated with earlier menopause generally.

How is POI diagnosed?

Diagnosis is based on two criteria, both of which must be met.

First, at least four months of irregular or absent periods in a woman under 40. Second, elevated FSH blood levels (follicle-stimulating hormone: a hormone that rises when the ovaries are not producing sufficient oestrogen, measured via a blood test) above 25 IU/L on two separate tests at least four weeks apart. A single elevated FSH result is not sufficient for diagnosis. Equally a single non-elevated FSH level does not rule out POI.

Oestradiol levels are typically low in POI and will usually be checked alongside FSH. The 2024 international guideline also recommends additional investigations to identify the underlying cause and assess long-term health risks. These may include:

• Karyotype (chromosomal analysis)
• Fragile X testing
• Autoimmune antibody screen (thyroid antibodies, adrenal antibodies)
• Bone density scan (DEXA scan) at diagnosis, given the risk of accelerated bone loss from inadequate oestrogen levels

A 2025 study published in the Journal of Clinical Medicine, examining 168 women at the time of POI or early menopause diagnosis, found that 43.1% already had osteopenia (lower-than-normal bone density) and 10.3% had osteoporosis (bone thinning disorder) at diagnosis. The study found a significant negative correlation between time to diagnosis and bone mineral density: the longer the delay, the greater the bone loss already present at the time of diagnosis. Early investigation is not just preferable, it carries real health consequences.

Why is POI sometimes missed or delayed?

Diagnostic delay in POI is a huge problem. The 2024 international guideline explicitly flags it as a driver of worse outcomes, and the bone health data above illustrates why: every month without treatment is a month where bone continues to lose density in the absence of adequate oestrogen.

While reasons for delay might be understandable, the consequences are not acceptable. A woman in her 20s presenting with fatigue, mood changes, and irregular periods is far more likely to be investigated for thyroid disease, stress, or depression than for POI. Hot flushes in a 30-year-old usually lead to investigations for possible infections and even cancer, but not for POI. Brain fog in any young woman is more likely to be attributed to stress, lifestyle factors, or mental health than POI.

A 2025 clinical review in the Cleveland Clinic Journal of Medicine describes POI as "overlooked and undertreated," noting that the combination of low clinical awareness and symptom overlap with common conditions creates systematic diagnostic delay across healthcare settings.

If your symptoms have been attributed to stress, depression, or thyroid problems without FSH testing, and you are under 40 with irregular or absent periods, you have the right to ask specifically for FSH to be checked. If your GP is uncertain, a referral to a specialist in reproductive medicine or menopause is appropriate under NICE guidance.

Treatment: HRT and why it matters more in POI than in standard menopause

HRT in POI is physiological replacement: restoring hormones to the levels that should naturally be present in a woman of that age. When a woman in her 30s has the oestrogen levels of a 55-year-old, HRT is not introducing hormones her body would not otherwise have: it is correcting a deficiency.

The risk framework is therefore fundamentally different. The Women's Health Initiative (WHI) trial, which generated widespread concern about HRT in the early 2000s, studied women who were on average in their early 60s, many of whom had been postmenopausal for over a decade. Its findings do not apply to women with POI. The 2025 Cleveland Clinic Journal of Medicine review made this quite clear: WHI findings should not be used to justify withholding hormone therapy from women with POI. NICE guidelines (NG23, updated 2026) are equally clear: HRT should be offered to women with POI unless specifically contraindicated.

Two treatment options are recommended by NICE

Hormone Replacement Therapy (HRT): For women with POI, HRT typically involves oestrogen combined with progestogen (for women with a uterus). Transdermal oestrogen (patches, gels, or sprays) is preferred from a cardiovascular risk perspective.

Combined hormonal contraceptive (CHC): the combined pill can provide the same hormonal replacement needed in POI while also providing contraception (addressed further in the fertility section) and for women for whom contraception is a priority, this may be the first-line choice.

One guidance point that is rarely communicated clearly: the 2024 international guideline and NICE both recommend continuing HRT until at least the average age of natural menopause, around 51. Stopping earlier, without clinical reason, removes the protection it provides during a period when the body would normally have maintained its own oestrogen levels.

If you have concerns about HRT and your personal or family health history, a specialist can assess your individual situation and discuss the full picture with you.

Long-term health implications, and how treatment protects you

POI without treatment carries meaningful long-term health consequences, because oestrogen deficiency from a young age has effects on multiple body systems and timely treatment significantly reduces those risks.

Bone health

Oestrogen plays a central role in maintaining bone density. Without it, bone loss accelerates. A 2023 review in the Journal of Clinical Medicine found that osteoporosis prevalence in women with POI ranges from 8 to 27%, and that HRT significantly increases bone mineral density in the lower spine and hip. After three years of HRT, bone mineral density in women with POI can be raised to levels comparable with premenopausal women. Getting a baseline DEXA scan when POI is first diagnosed is therefore crucial.

Cardiovascular health

Women with POI have a higher risk for heart disease compared to women who experience menopause at the typical age. A 2023 systematic review and meta-analysis published in Reviews in Cardiovascular Medicine, examining data from 40,549 women with POI and over one million controls, found that women with POI had a 35% higher risk of cardiovascular events and a 42% higher risk of coronary heart disease.

Cognitive health

Emerging research suggests that prolonged oestrogen deficiency from a young age may be associated with increased risk of dementia and Parkinson's disease later in life. The evidence is still developing and does not yet support definitive clinical recommendations; however, it supports the broader case for not delaying treatment.

POI and fertility: what you need to know

For most women with POI, natural conception is unlikely but not impossible. The ovaries are not functioning reliably, so ovulation is intermittent and the hormonal environment needed to support a pregnancy is disrupted.

However, because ovarian function in POI is intermittent rather than entirely absent, spontaneous ovulation can still occur. The 2024 international guideline estimates that up to 5-10% of women with POI may conceive naturally. This figure is not offered as a source of false hope but it has an important practical implication. HRT does not provide contraception so if a woman with POI does not wish to become pregnant, contraception needs to be discussed.

For women who do wish to conceive, the most common options include egg donation, embryo adoption, and egg or embryo freezing. These conversations are best had with a fertility specialist as early as possible after diagnosis.

The emotional impact of a POI diagnosis

“A POI diagnosis in your 20s or 30s is not just a medical event. It is an identity disruption, often arriving without warning, at an age when most peers are nowhere near thinking about menopause. The shock of being told your ovaries are not working normally, combined with the implications for fertility and long-term health, can trigger a profound reaction.”

Katy Jackson, Clinical Director - Women's Health

The 2024 international guideline explicitly recognises the psychological impact of POI as a clinical priority and recommends psychological support as part of a multidisciplinary approach to care.

The feelings that commonly follow a POI diagnosis include: grief for anticipated fertility, anger at the time lost before diagnosis, anxiety about long-term health consequences, shame or self-consciousness about symptoms that feel "wrong" for your age, and isolation from peers who are not sharing this experience. Connecting with others who understand is one of the most consistently helpful things women with POI describe. The Daisy Network (daisynetwork.org) is the UK's dedicated POI support charity and provides peer support, information, and a community of women navigating this diagnosis.

Where to get the right support

A POI diagnosis requires specialist care. NICE guidance recommends referral to a specialist with expertise in menopause or reproductive medicine where there is uncertainty about diagnosis or management. Given that diagnostic delay is common and that the consequences of under-treatment are significant, seeking specialist input early makes a real difference.

A 45-minute consultation with a BMS-trained menopause specialist gives you the time to explore your full symptom picture, your diagnosis, your treatment options, and your concerns, including those about HRT, fertility, and long-term health. That is very different from a brief GP appointment where POI may be an unfamiliar territory.

Voy's menopause service includes tailored HRT, blood test monitoring including oestradiol and FSH, testosterone assessment where relevant, and a care model built around individual clinical need rather than a one-size prescription. In Voy's outcome data, 88% of members reported feeling more hormonally balanced at three months, compared to 62% receiving standard care: a signal of what personalised, specialist-led hormonal care can achieve. (This data reflects Voy's broader menopause population, not a POI-specific cohort, and should be understood in that context.)

If you would like to understand your options and what specialist menopause care looks like in practice, find out what support might be right for you.

This content is for informational purposes and does not constitute medical advice. Always consult a healthcare professional.